Mouse Anti-Morphine Monoclone Antibody Drug of Abuse For IVD Manufacture

Background:

Morphine is thought to produce reinforcement phenomena via stimulation of mu, delta, and kappa opioid receptors that regulate stress perception, pain control, reward behavior, and neurohormone secretion in reward-relevant brain systems. It has the highest affinity for mu, followed by delta and kappa. Rapid activation of the mu opioid receptor by morphine results in a euphoric phenotype, thus conferring the reinforcing effects of the drug. This activation is accompanied by extracellular dopamine re-lease, which alters several events related to the cAMP signal transduction pathway. Of particular significance is that CREB seems to be modified by morphine, thereby affecting addictive behavioral phenomena, such as withdrawal symptoms.

Opioid analgesics comprise a large group of substances which control pain by depressing the central nervous system. Large doses of Morphine can produce higher tolerance levels and physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.

Specification:

Description: Monoclonal Antibody to Morphine

Specificity: This antibody reacts with morphine.

Host Animal: Hybridization of P3x63-Ag 9.653 myeloma cells with spleen cells from

Balb/c mouse

Isotype: IgG1, kappa light chain

Source: Mouse ascites

Immunogen: Morphine-BSA

Format: Purified, liquid

Purification: Protein G chromatography

Concentration: 2.72 mg/mL (OD280 nm, E^0.1% = 1.40)

Affinity Constant: Not determined

Buffer: 0.015M potassium phosphate buffer, 0.85% NaCl, 0.05% NaN₃ pH=7.2

Pairing Assays: N/A

Purity: >95% by HPLC and SDS-PAGE

Application: Morphine quantitative assays by EIA

Storage: 2-8^o C for 1 year; -20⁰ C for long term